• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

上皮细胞中肿瘤坏死因子受体TNFRSF1A的基因型与转录本加工:对囊性纤维化生存的影响

Genotype and transcript processing of the tumour necrosis factor receptor TNFRSF1A in epithelial cells: implications for survival in cystic fibrosis.

作者信息

Uden Alexander, Dunsche Inga, Janciauskiene Sabina, Gräber Simon, Feng Longhua, Tamm Stephanie, Hedtfeld Silke, Stege Gesa, Jahn Kirsten, Kontsendorn Julia, Alfeis Nadine, Kühbandner Iris, Minso Rebecca, Dopfer Christian, Griese Matthias, Sommerburg Olaf, Ringshausen Felix C, Nährlich Lutz, Hansen Gesine, Welte Tobias, Braubach Peter, Mall Marcus A, Tümmler Burkhard, Dittrich Anna-Maria, Stanke Frauke

机构信息

Department for Paediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany; Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), German Center for Lung Research (DZL), Germany.

Department for Paediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany.

出版信息

EBioMedicine. 2025 Jul 10;118:105848. doi: 10.1016/j.ebiom.2025.105848.

DOI:10.1016/j.ebiom.2025.105848
PMID:40645008
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12275981/
Abstract

BACKGROUND

Cystic fibrosis is caused by mutations of the cystic fibrosis transmembrane conductance regulator, CFTR, an epithelial anion transport protein, responsible for, inter alia, sputum viscoelasticity in the lung. We previously identified the TNF receptor superfamily 1A TNFRSF1A (TNFR1) as a genetic modifier of CFTR function and disease severity in the CF twin and sibling study population. We aimed to replicate our findings in independent cohorts, assess the role of TNFR1 for patient survival and identify functional changes associated with TNFR1 polymorphisms.

METHODS

We incorporated data from three independent long-term mono- and multicentric cohorts of people with cystic fibrosis (pwCF) to confirm the previously described association of TNFR1 with CFTR function and to extend our study to include survival data for our local cohort and a pan-European cohort of pwCF. We studied TNFR1 transcripts obtained from primary airway epithelia grown as air-liquid interface cultures to address possible mechanisms involved in up-stream and down-stream effects of TNFR1.

FINDINGS

Survival differed by more than a decade when comparing carriers of contrasting TNFR1 genotypes among unrelated pwCF as well as among CF siblings pairs. The presence of the TNFR1 transcript variant TNFR1delEx2 in primary airway epithelia was associated with TNFR1 genotype.

INTERPRETATION

The association of the TNFR1 transcript variant TNFR1delEx2 associates with the TNFR1 genotype, possibly mediating the genotype-survival association we found regarding TNFR1 genotype and patient survival in cystic fibrosis.

FUNDING

Supported by the German Ministry for Education and Research (BMBF) (82DZL009B1 to MAM and 82DZL002A1, to GH, BT, AMD, FS) and the Mukoviszidose Institut gGmbH (MI-2002, to LN, AMD, FS).

摘要

背景

囊性纤维化由囊性纤维化跨膜传导调节因子(CFTR)突变引起,CFTR是一种上皮阴离子转运蛋白,尤其负责肺部痰液的粘弹性。在囊性纤维化双胞胎和同胞研究人群中,我们先前确定肿瘤坏死因子受体超家族1A(TNFRSF1A,TNFR1)是CFTR功能和疾病严重程度的遗传修饰因子。我们旨在在独立队列中重复我们的发现,评估TNFR1在患者生存中的作用,并确定与TNFR1多态性相关的功能变化。

方法

我们纳入了来自三个独立的长期单中心和多中心囊性纤维化患者(pwCF)队列的数据,以确认先前描述的TNFR1与CFTR功能的关联,并将我们的研究扩展到包括我们本地队列和泛欧洲pwCF队列的生存数据。我们研究了从气液界面培养的原代气道上皮细胞中获得的TNFR1转录本,以探讨TNFR1上游和下游效应可能涉及的机制。

结果

在不相关的pwCF以及CF同胞对中,比较具有不同TNFR1基因型的携带者时,生存期相差超过十年。原代气道上皮细胞中TNFR1转录本变体TNFR1delEx2的存在与TNFR1基因型相关。

解读

TNFR1转录本变体TNFR1delEx2与TNFR1基因型相关,可能介导了我们在囊性纤维化中发现的TNFR1基因型与患者生存之间的基因型-生存关联。

资助

由德国教育和研究部(BMBF)(授予MAM的82DZL009B1以及授予GH、BT、AMD、FS的82DZL002A1)和穆科维齐多斯研究所(授予LN、AMD、FS的MI-2002)资助。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69e6/12275981/d5bb7a8f7f95/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69e6/12275981/4efed9deb0e1/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69e6/12275981/cf96e042e8b8/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69e6/12275981/63e8b00a2fc5/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69e6/12275981/d5bb7a8f7f95/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69e6/12275981/4efed9deb0e1/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69e6/12275981/cf96e042e8b8/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69e6/12275981/63e8b00a2fc5/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69e6/12275981/d5bb7a8f7f95/gr4.jpg

相似文献

1
Genotype and transcript processing of the tumour necrosis factor receptor TNFRSF1A in epithelial cells: implications for survival in cystic fibrosis.上皮细胞中肿瘤坏死因子受体TNFRSF1A的基因型与转录本加工:对囊性纤维化生存的影响
EBioMedicine. 2025 Jul 10;118:105848. doi: 10.1016/j.ebiom.2025.105848.
2
Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).针对携带 II 类 CFTR 基因突变(最常见的是 F508del)的囊性纤维化患者的校正治疗(有或没有增效剂)。
Cochrane Database Syst Rev. 2023 Nov 20;11(11):CD010966. doi: 10.1002/14651858.CD010966.pub4.
3
Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis.依伐卡托(Ataluren)及类似化合物(针对 I 类提前终止密码子突变的特异性治疗药物)治疗囊性纤维化。
Cochrane Database Syst Rev. 2023 Mar 3;3(3):CD012040. doi: 10.1002/14651858.CD012040.pub3.
4
Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease.用于囊性纤维化相关肺部疾病的局部囊性纤维化跨膜传导调节因子基因替代疗法。
Cochrane Database Syst Rev. 2016 Jun 17;2016(6):CD005599. doi: 10.1002/14651858.CD005599.pub5.
5
Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.囊性纤维化的增效剂(针对III类和IV类突变的特定疗法)。
Cochrane Database Syst Rev. 2015 Mar 26(3):CD009841. doi: 10.1002/14651858.CD009841.pub2.
6
Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis.用于治疗囊性纤维化的阿他芦醇及类似化合物(针对I类提前终止密码子突变的特定疗法)。
Cochrane Database Syst Rev. 2017 Jan 19;1(1):CD012040. doi: 10.1002/14651858.CD012040.pub2.
7
Airway clearance techniques compared to no airway clearance techniques for cystic fibrosis.气道清除技术与囊性纤维化的非气道清除技术比较。
Cochrane Database Syst Rev. 2023 Apr 12;4(4):CD001401. doi: 10.1002/14651858.CD001401.pub4.
8
Antibiotic treatment for non-tuberculous mycobacteria lung infection in people with cystic fibrosis.囊性纤维化患者非结核分枝杆菌肺部感染的抗生素治疗
Cochrane Database Syst Rev. 2025 Mar 27;3(3):CD016039. doi: 10.1002/14651858.CD016039.
9
Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease.用于囊性纤维化相关肺部疾病的局部囊性纤维化跨膜传导调节因子基因替代疗法。
Cochrane Database Syst Rev. 2013 Nov 26(11):CD005599. doi: 10.1002/14651858.CD005599.pub4.
10
Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease.用于囊性纤维化相关肺部疾病的局部囊性纤维化跨膜传导调节因子基因替代疗法。
Cochrane Database Syst Rev. 2012 Oct 17;10:CD005599. doi: 10.1002/14651858.CD005599.pub3.

本文引用的文献

1
Progress of personalized medicine of cystic fibrosis in the times of efficient CFTR modulators.高效CFTR调节剂时代囊性纤维化个性化医疗的进展
Mol Cell Pediatr. 2025 May 5;12(1):6. doi: 10.1186/s40348-025-00194-0.
2
Targeting the TNF and TNFR superfamilies in autoimmune disease and cancer.针对自身免疫性疾病和癌症中的 TNF 和 TNFR 超家族。
Nat Rev Drug Discov. 2024 Dec;23(12):939-961. doi: 10.1038/s41573-024-01053-9. Epub 2024 Oct 24.
3
Targeting TNF/TNFR superfamilies in immune-mediated inflammatory diseases.针对免疫介导的炎症性疾病中的 TNF/TNFR 超家族。
J Exp Med. 2024 Nov 4;221(11). doi: 10.1084/jem.20240806. Epub 2024 Sep 19.
4
Impact of elexacaftor/tezacaftor/ivacaftor therapy on lung clearance index and magnetic resonance imaging in children with cystic fibrosis and one or two alleles.依洛尤单抗治疗对伴有一个或两个 等位基因突变的囊性纤维化儿童的肺清除指数和磁共振成像的影响。
Eur Respir J. 2024 Sep 5;64(3). doi: 10.1183/13993003.00004-2024. Print 2024 Sep.
5
Pharmacological Improvement of Cystic Fibrosis Transmembrane Conductance Regulator Function Rescues Airway Epithelial Homeostasis and Host Defense in Children with Cystic Fibrosis.药物改善囊性纤维化跨膜电导调节因子功能可挽救囊性纤维化患儿的气道上皮稳态和宿主防御。
Am J Respir Crit Care Med. 2024 Jun 1;209(11):1338-1350. doi: 10.1164/rccm.202310-1836OC.
6
A Fast Scoring of Human Primary Respiratory Epithelia Grown at Air-Liquid Interface (ALI) to Assess Epithelial Morphology in Research and Personalized Medicine Settings.一种对在气液界面(ALI)培养的人原发性呼吸道上皮进行快速评分的方法,用于在研究和个性化医疗环境中评估上皮形态。
J Pers Med. 2024 Jan 18;14(1):109. doi: 10.3390/jpm14010109.
7
Inflammatory Activity of Epithelial Stem Cell Variants from Cystic Fibrosis Lungs Is Not Resolved by CFTR Modulators.囊性纤维化肺部上皮干细胞变体的炎症活性不能被 CFTR 调节剂解决。
Am J Respir Crit Care Med. 2023 Nov 1;208(9):930-943. doi: 10.1164/rccm.202305-0818OC.
8
Epithelial TNF controls cell differentiation and CFTR activity to maintain intestinal mucin homeostasis.上皮细胞 TNF 控制细胞分化和 CFTR 活性以维持肠道粘蛋白的动态平衡。
J Clin Invest. 2023 Oct 16;133(20):e163591. doi: 10.1172/JCI163591.
9
Cystic Fibrosis Reprograms Airway Epithelial IL-33 Release and Licenses IL-33-Dependent Inflammation.囊性纤维化重编程气道上皮细胞 IL-33 的释放并激活 IL-33 依赖性炎症。
Am J Respir Crit Care Med. 2023 Jun 1;207(11):1486-1497. doi: 10.1164/rccm.202211-2096OC.
10
Airway epithelial type-2 alarmin profiles: Blood eosinophil counts remain in memory.气道上皮2型警报素谱:血液嗜酸性粒细胞计数保持记忆状态。
Eur J Immunol. 2023 Apr;53(4):e2250101. doi: 10.1002/eji.202250101. Epub 2023 Mar 6.